APA (7th ed.) Citation

Ford, J. H., Kurth, T., Starling, A. J., Ayer, D. W., Wietecha, L. A., Port, M. D., . . . Ruff, D. D. (2020). Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine. Headache, 60(10), 2304-2319. https://doi.org/10.1111/head.14013

Chicago Style (17th ed.) Citation

Ford, Janet H., Tobias Kurth, Amaal J. Starling, David W. Ayer, Linda A. Wietecha, Martha D. Port, Mallikarjuna Rettiganti, and Dustin D. Ruff. "Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine." Headache 60, no. 10 (2020): 2304-2319. https://doi.org/10.1111/head.14013.

MLA (9th ed.) Citation

Ford, Janet H., et al. "Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine." Headache, vol. 60, no. 10, 2020, pp. 2304-2319, https://doi.org/10.1111/head.14013.